Trial Profile
A Phase 2, Randomized, Open-Label, Dose Titration, Safety and Efficacy Study of FG-4592 for the Correction of Anemia in Newly Initiated Dialysis Patients Not on Erythropoiesis-Stimulating Agent Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2021
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary) ; Ferric gluconate; Ferrous fumarate; Ferrous gluconate
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors FibroGen
- 01 Sep 2021 Number of treatment arms have been increased from 1 to 4 by the addition of experimental arms consisting of arms B (PO iron), arm C (IV iron) and arm D (PO iron), where different doses and forms of iron are administered along with Roxadustat, in the form of Ferrous Fumarate, ferrous gluconate (oral) or ferric gluconate (IV).
- 21 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jan 2014 New trial record